Blueberries Medical Corp. is engaged in the production and distribution of psychoactive and non-psychoactive cannabis by-products. The company is headquartered in Toronto, Ontario. The company went IPO on 2014-04-09. The firm is fully licensed for the cultivation, production, domestic distribution, and international export of cannabidiol (CBD) and tetrahydrocannabinol (THC)-based medical cannabis in Colombia. The firm is focusing on cultivating, processing, and supplying medicinal-grade Cannabis oil extracts, medical flowers, and related products. Additionally, the Company distributes functional supplements, wellness products, and natural ingredients. The Company’s subsidiaries include Blueberries Research Corporation (BRC) and Blueberries SAS (BBSAS). BBSAS is a licensed producer and distributor of medicinal Cannabis and Cannabis-derived products in Colombia.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for BBRRF. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: BBRRF is a Buy candidate.
BBRRF stock price ended at $0.01 on 星期五, after rising 0.00%
On the latest trading day Feb 13, 2026, the stock price of BBRRF rose by 0.00%, climbing from $0.01 to $0.01. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.01 and a high of $0.01. Alongside this price increase, trading volume also rose by 36.2K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 23.7K shares were traded, amounting to a market value of approximately --.